BioXyTran

BioXyTran is a clinical-stage biotech leveraging proprietary carbohydrate chemistry to develop therapeutics across two core platforms: antiviral entry inhibitors and oxygen transport molecules for hypoxia. Founded in 2014 and led by carbohydrate chemistry expert Dr. David Platt, the company is advancing its pipeline through preclinical and clinical development. Its strategy focuses on creating first-in-class treatments for large markets with high unmet need, including viral infections and ischemic conditions, aiming to deliver value through platform validation and strategic partnerships.

Two carbohydrate-based platforms: 1) Glycovirology for viral entry inhibition via lectin mimetics, and 2) Oxygen therapeutic platform using a synthetic nanoscale carrier to treat hypoxia and prevent necrosis.

Faces competition from established players in antivirals (mAbs, small molecules) and oxygen therapeutics (failed HBOCs, hyperbaric therapy). Differentiation lies in its unique carbohydrate-based mechanisms, which, if proven safe and effective, could offer advantages in broad-spectrum activity and tissue oxygenation without the toxicity of past approaches.